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While the ﬂow of information from the genome to the arrangement
and function of cells, the relationship between genotype and pheno-
type, will be the occupation of biologists for another century, for the
physician the order is reversed. Patients present with a clinical pheno-
type and we ask our doctors four questions:
• What is the name and cause of my condition?
• What will happen to me?
• What can be done about it?
• Who can help me?
I have spent the last 11 years seeking those answers on behalf of my
daughter Beatrice.
Our third child, Beatrice or Bea, was born in 2003 with contracted
ﬁngers (arthropgryposis) andwide eyes (hypertelorism). The attending
pediatrician noted shewas a bit ﬂoppy. Yet no connections among these
or other clinical ﬁndings were known to medicine. Those highly direct-
ed, system-speciﬁc physical exams by various specialists added to the
list of physical ﬁndings but yielded no plausible comprehensive diagno-
sis and left me, a physician trained in medical genetics, concerned that
something was being overlooked. Scared is the better word.
Bea was not gaining weight principally because the growth of her
muscles was not keeping up with the growth of her skeleton. Further-
more, she did not achieve in a timely fashion her grossmotormilestones
such as holding her head up, sitting up, cruising and walking. This was
ominous and distressing because we had little idea why this was the
case, nor what to expect or what to do. Lisa, my wife, breastfed and
did all she could to get calories into Bea, to no avail. Nothing is more
frustrating to a mother that an apparent inability to grow her children.
At the age of 6months Beawas admitted to the hospital with a diag-
nosis of failure to thrive; the differential diagnosis of is very long and
frightening. There seemed an overwhelming number of possible expla-
nations: was it an acquired condition caused by a parasite or infection?
Was it birth trauma? Was it genetic? I favored a genetic cause simply
because it seemed unlikely that the numerous different signs and symp-
toms we observed in Bea would have different etiologies. I also knew
that many syndromes manifest at birth have as their cause a genetic
variation. Her hospital course was characterized by confusion over
who was driving the case: were the neurologists primarily in charge,E-mail address: hyrjr@yahoo.com.
http://dx.doi.org/10.1016/j.atg.2016.01.006
2212-0661/© 2016 The Author. Published by Elsevier B.V. This is an open access article underor the gastrointestinal doctors, or was it the developmental expert?
They all seemed to be working at cross-purposes each stabbing in the
dark with their preferred work-up. But each expert had no name for
Bea's condition or strong reasons to biopsy this nerve or radiograph
that organ. Bea was home safe within 48 h with a prescription for ﬂax
seed oil.
After two years, we knew we had hit a dead end with the local
experts. Lisa managed logistics: taking Bea to occupational therapy,
physical therapy, the orthotic maker, and Bea's doctor. I focused on
tactics: how to identify a unifying cause of Bea's syndrome. As Bea's
daily care reached equilibrium and we settled into the belief that Bea
was not acutely ill or going downhill, I realized I had to assume respon-
sibility for the search rather than wait patiently for the science to catch
up to Bea. All parents in this situation, where the medical authorities
have essentially given up, learn the same lesson. They are their children's
most dogged advocates. And each does as much as is within his or her
power, nothing less. So what could I do?
2. Telltale toes
Early on I had a hunch Bea's condition was related to Marfan syn-
drome because her long feet and long, thin ﬁngers and toes closely re-
sembled those of Marfan patients, though she had none of the
essential diagnostic features of that syndrome (Loeys et al., 2010).
When Bea was three, I took her to be examined by my former teacher
and Marfan expert, Dr. Victor McKusick (McKusick, 1960). A training
fellow in clinical genetics examined Bea and noticed that she had a
biﬁd uvula (amild cleft in the soft palate). A Japanese and independent-
ly an Italian group had identiﬁed in Marfan-like patients mutations in
the TGFβ receptor genes (Disabella et al., 2006; Mizuguchi et al.,
2004). The TGFβ growth factor hormones named for their ability to
transform normal cells to cancer cells were also known to be involved
in many aspects of development including the soft palate (Kaartinen
et al., 1995; Proetzel et al., 1995). Her biﬁd uvula further supported
the notion of TGFβ involvement though there were many potential can-
didate proteins involved in the TGFβ signaling pathways (Derynck and
Miyazono, 2008). Nevertheless, this greatly focused my efforts despite
the spooky thought of cancer on the horizon or the complications of a
Marfan-like disease.
I soon generated a hypothesis based on the work of Dr. Se-Jin Lee, a
professor at JohnsHopkins, a graduate studentwhenwe ﬁrstmet. Se-Jin
had discovered that muscle development, speciﬁcally muscle size, was
regulated by a hormone he named myostatin (aka GDF-8) that wasthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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three TGFβ factors (McPherron et al., 1997). The TGFβ hormones even
used the same receptors as myostatin (Lee et al., 2005). Se-Jin showed
in mice that too little myostatin allowed muscles to grow abnormally
large. He also reported on one Herculean child with mutations in both
myostatin genes (Schuelke et al., 2004). There were, however, no re-
ported cases of excess myostatin signaling that might limit muscle
development—could this be my Bea's problem?
With a neat hypothesis in hand and the proverbial laboratory “help
from my friends”, we sequenced the myostatin receptor genes in Bea's
DNA reasoning that a single new gain-of-function mutation in a
myostatin receptor might enhance signaling and diminish muscle size.
As enamored as I was with the hypothesis, a year into that work, it
was clear Bea's myostatin receptor genes were genetically normal. But
the effort was not fruitless. I had met with or spoken to many of the
experts in TGFβ signaling. I was now familiar with their literature and
could discuss with researchers the issues beyond what had been pub-
lished as only those who have ﬁrst-hand experience generating and
analyzing data can. But making and testing serial hypotheses looked
like a long and winding and maybe endless road.
3. Ome sweet ome
When I found myself stumped, slightly dejected or a year from my
last visit, I e-mailed Professor Andy Fire at Stanford down the road
from my house. Andy has a calming and unassuming way of walking
through a problem and seeing where potential solutions lie. There is
an uncommon clarity to his thinking always rendered in an understated
manner. Explaining that it had taken me an inordinate amount of time
to get sequence data on only four genes, all of whichwere unperturbed,
he suggested what seemed preposterous: look at 100 genes at a time as
hewas doingwith the then-newmassively parallel sequencing technol-
ogy he was prototyping. “Go genomic old man,”was the advice I heard.
It was 2007; Beawas four years old. Clinically shewas stable so I felt I
had time to take a more exhaustive approach. My needs were beyond
what I could do with my own hands. Now was the time to move the
project out of my attic and into the wider world. The idea to scale-up
sequencing was appealing but technologically beyond my capability.
I thought my best chances of accessing such technology and the
knowhow to use it were with the biotech companies, but the few I
contacted were consumed with their own projects.
That summer of 2007 I inadvertently stepped into the public spot-
light when I gave a talk at Google on what I called The Bea Project:
parents dealing with a genetic unknown and do-it-yourself (when
nobody else will) biology. I presented my quixotic efforts to identify a
mutation in the myostatin receptor genes. Brendan Maher, a reporter
from Nature interested in personal genomics got wind of my talk. He
saw in Bea and me a story of very personal genomics and an era that
had come of age because of the broad accessibility of technology to
studyDNA. His article and a cover picture of Bea appeared in October, co-
incidentwith amajor geneticsmeeting and Bea became amicrocelebrity
(Maher, 2007).
That same month I attended a small biotech meeting. Present was
Jay Flatley, CEO of Illumina, the leading manufacturer of sequencing
equipment. I had known Jay informally from eight years earlier. I
reintroduced myself; he had read the story about Bea. I screwed up
my courage to ask the big question: would Illumina help sequence
my daughter's DNA? At that time a whole genome sequence cost
$350,000. Jay made no promises but said if Dr. Gary Schroth, one of
Illumina's sequencing gurus, was interested, he was okay with helping.
That night I emailed Schroth. Over the next three years Gary and his
team sequenced the family's transcriptomes (all of our expressed
genes), our whole genomes (at low coverage), and lastly our exomes.
Why? In part because the data sets were useful to Illumina to cross-
validate its own technology platforms, reﬁne its software algorithms
with two generations of data, and to test sequencing technologies notyet ready for the market. Not that Illumina was uninterested in Bea's
mystery and being part of a discovery—they were; Gary and his team
had already made many technological breakthroughs collaborating
with legions of investigators. Jay had picked the right person: Gary
was a terriﬁc collaborator because of his unwavering enthusiasm and
his scientiﬁc creativity.
Eighteen months later, in 2009, Gary had lightly sequenced the
entirety of the family's genomes looking for major changes in the DNA
and our transcriptomes with high ﬁdelity. These were very formidable
datasets to analyze but they yielded nothing that smacked of an answer
tome or to Irina Khrebtukova, a computer scientist cum bioinformaticist
on Gary's team. We observed many interesting bits of biology in what
was probably the ﬁrst family so extensively studied genomically. But if
medicine is the art of assessing probabilities, all the new hypotheses
seemed like long shots. Nothing directly connected with TGFβ popped
up, thoughwe tried hard to make those connections. We felt compelled
to follow-up on many variants and had long discussions with scientists
who had real expertise in one gene or another. Gary and I presented our
data at the ﬁrst Cold Spring Harbormeeting on Personal Genomics hop-
ing someone might see something we didn't. Except for kind words of
encouragement from George Church, a loyal fan of patient initiatives,
we were ignored.
4. Pay dirt
Negative data are dark clouds and heavy rain on any parade and
the words “keep looking” is a trying refrain. But perhaps because I
was so convinced there had to be a causative variation that
“explained” Bea's condition, Gary sequenced our exomes, ostensibly to
test Illumina's exome capture kit in development. As the data ﬂowed
to Irina, now skeptical of my ideas after two years of mining data, I
reminded her to be on the lookout for any gene variant speciﬁc to Bea
with the letters “TGF” in the name. On the Saturday afternoon 7th of
November 2010, Irina emailed me saying: “Looks like you were right.”
Bea alone among the family had a highly damaging variant in the
TGFβ3 gene. By the end of the weekend it was clear from the literature
that such a variant would disrupt the structure of the TGFβ3 protein
(Daopin et al., 1992;Mittl et al., 1996). In fact, two decades earlier some-
one had mutated that very codon and showed that the resultant
hormone was inactive (Brunner et al., 1992). Another paper showed
TGFβ3 was essential for fusion of the soft palate during fetal develop-
ment (Nawshad and Hay, 2003). From that moment on it was all
about TGFβ3.
The next few years were occupied with the next logical step—
understanding the effects of Bea's TGFβ3 mutation. It was not enough
to know that Bea had this variant. There were no reports of mutations
in the coding region of the TGFβ3 gene. As well, there was a very scant
usable literature on the TGFβ3 protein.
Like Diogenes, I looked for an honest man who also was a TGFβ ex-
pert. A friend and scientiﬁc conﬁdante studying muscle development
suggested I meet Professor Malcolm Russell Whitman at Harvard, a
bona ﬁde TGFβmaven.We struck up a collaboration to study the effects
of the mutation on the function of the TGFβ3 protein. Over the next
year, he and his colleagues in Korea were able to show very clearly
that themutant protein was by itself inactive—no downstreammolecu-
lar signaling could be detected—but because the TGFβ3 hormone has
two identical components (a dimer), the mutant version also inhibited
the wild-type protein. Bea's variant protein reduced TGFβ3 signaling
by about 75% qualifying the mechanism as dominant-negative.
Phenotypes are ﬂuid and as the body grows or as it ages, signs and
symptoms come and go. Bea's widely spaced eyes grew close enough
over the years to be called “normal”; one leg becamemanifestly weaker
than the other while all of her cardiac parameters and great vessel
dimensions remained well within the normal range. The extent of a
phenotype is also dependent on how hard one is willing to look—brain
biopsies are not a routine part of the work-up. Bea at seven years still
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same little girl Dr. McKusick had examined.
Bea had not been re-examined by a geneticist since she was three
years old. In December of 2011, I was asked by a friend to present the
story of Bea tomedical students in Vancouver. I obliged for two reasons.
First, I felt the need to convey the dual perspective of physician and
father. Second, I also knew of Dr. Judy Hall at the University of British
Columbia, who had spent some of her celebrated career studying
amyoplasia congenita, a mix of heritable conditions involving muscle
development. I had read some of her work when Bea was very young
and did not see the connection so I put amyoplasia in the back of my
head. But Dr. Hall was a legendary clinician trained under Dr. McKusick,
so I called to ask if we could meet.
I gavemy talk to the students and on theway to the airportmet Judy
in her crowded ofﬁce. Her enthusiasm and willingness to help almost
overwhelmed me. We suggested she examine Bea while attending a
pediatric meeting in Carmel, California. Perfect. Two months later, Bea
and I trundled off to meet Judy in her hotel where she proceeded to
examine Bea in fantastic detail providing the best physical exam Bea
had ever had. I took notes while Judy narrated the entire landscape
of Bea from crown to heel. She measured the length of her limbs and
the angles of her joints. She examined Bea's hand like a palm reader.
“This distal digital crease is formed at Week 12 of fetal development
and its absence tells uswhen the problembegan,” she said. It was amar-
vel to behold and a ringing afﬁrmation of what keen clinical observation
can yield.
In 2013, Judy and I, along with Malcolm, Gary, their respective
teams and others published a case report describing Bea in clinical and
molecular detail. The paper identiﬁed the variation in the TGFβ3
gene likely responsible for her phenotype and the histological, cell bio-
logical and biochemical data to support a likely mechanism of action: a
hypomorphic hormone providing inadequate TGFβ3 signaling during
in utero muscle and skeletal development (Rienhoff et al., 2013). The
primary purpose of the report was to alert clinicians to this new
syndrome so we might ﬁnd other Beas… or TGFβ3 variants. It was the
clearest science and the most carefully crafted piece of writing I had
ever produced. The work was done by a band of people who had
never met, who did not even know each other professionally and
who, for the most part, spent their own time and money to do the
work. That in itself seemed miraculous.
5. Modus operandi
What kind of project was—and is—The Bea Project, one with many
sequential and technically complex steps, heavily dependent on good-
will and the availability of the right technology, conducted in an intel-
lectual state of affairs where there are more unanswered questions
about TGFβ signaling than good answers? How didwemake it happen?
I have a simple answer: I searched hard for people willing to help. There
were some who would not make allowances for my ignorance or my
status as a father or my non-academic status but many more said
“Yes”. It was vital to involve those who knew a great deal about a sub-
ject, those who actually did experiments and those who could provide
the needed sparks and leaps of imagination to keep the project moving
forward. It still astounds me that complete strangers could be moved to
pitch in. Some explained that making a small contribution to a collabo-
ration with a face, a name and, indeed, a mission was more gratifying
than working alone on some gene or cell line or mouse. For others,
it was their curiosity. For a few it was professional development, a no-
less important matter in the current academic environment. They
were all welcome.
But sheer opportunism played a role, too. Mywork in drug develop-
ment takes me to many hospitals and labs around the world. When my
schedule permitted, I took the opportunity to introducemyself to those I
thought could shed light on Bea-related clinical or biological questions
at hand. I prepared for those meetings by reading their work so myquestions were better informed and their answers more useful. Where
possible, I got introductions from informal advisors and collaborators.
It was hit or miss but most gave me a bit of their time, a few became
collaborators and some even friends.
6. Peek moments
There are two paths to understanding the relationship between
genotype and phenotype, a reductionistic but necessary ﬁrst exercise.
One is studying the natural experiment of human variation. The other
is the unnatural experiment: making in the laboratory a cell, a worm,
a ﬂy, a ﬁsh or a mouse with the exact genotype of interest. Professor
Tom Doetschman had spent his life studying the effects of mutations
in the TGFβ family of genes. Over the decades of his TGFβ research in
mice, hewas thoroughly familiarwith the complexities of TGFβ signaling
including the role “background genetics” of the mouse played in deter-
mining phenotype, a potential source of artifact and misinterpretation
if not carefully controlled (Doetschman, 2009). His publications after
25 years remain the most durable of the mouse TGFβ literature because
he provided a comprehensive and totally transparent description of
what he did and what he saw in mice. Dr. Doetschman was the man to
call.
To my great fortune, a cold call in December 2010 to Tom and
yielded within a year a TGFβ3+/TGFβ3C409Y mouse. Bea and I visited
Tucson in October 2011. We were escorted deep into the bowels of
the basic science building to the vivarium, past airlocks and passcodes,
to visit the mouse colony. Bea was dressed in a sterile gown that
dragged along the ﬂoor, gloves, booties and a mask that nearly covered
her face. Connie, the maus haus frau, introduced Bea to the varieties of
mice used in science, most with beautiful long tails and shiny coats
but with ears full of punch holes. The chimeras with Bea's gene were
running around happily. Bea was besotted. Surely against protocol, we
smuggled mouse #17 through the airport and on the plane. A service
mouse if anybody asked. Re-christened back to San Francisco as Almond
Joy because she liked the nuts and she was an instant joy to Bea, she
lived a very generous mouse life of 2.5 years before dying in front of
an attentive but teary Bea in a brief spasm of twitches and shakes.
Almond Joy is buried in the family graveyard beneath the front lawn,
next to two cats, two rabbits and a parakeet.
Almond Joy shone a bright light in Bea's life but a lesser light on our
genetic question. Almond Joy and her littermates appeared to our eyes
completely normal. She was a little chubby but Bea was an indulgent
mouse keeper. Being a TGFβ3+/TGFβ3C409Y heterozygote did not confer
any obvious phenotype involving muscle. It would have been a great
boon to the project to get any phenotype, which would then allow
us to study in detail the involvement of TGFβ3 in development. We
can accept for now that this TGFβ3 variant has no phenotype as a het-
erozygote, that mice are able to fully compensate for a signiﬁcant loss
of TGFβ3 activity during development. After all, mice are not always
human. But maybe this is not such a great disappointment; maybe
this speciﬁc variant is relatively benign. This is the seesaw that the
father rides on one end with the scientist on the other end.
The second way to understand the phenotypic effects of variants
in a gene is to “collect” patients, those that acquired their mutations
“naturally”. Not surprising, it matters a great deal which patient traits
one chooses to select for. An orthopedic clinic may see those with
contracted joints, the hand clinic those with clinodactyly, the ENT clinic
patients with biﬁd uvulas, and the cardiovascular clinic those with ab-
normalities in the aortic vasculature. Thus, each clinic has a bias toward
patients with particular features. It is a near certainty, however, that all
patients with hand problems will not all have vascular problems and
that those with contracted joints will not all have biﬁd uvulas. In prac-
tice, the more severe phenotypes such as vascular disease will initially
deﬁne the disease. Death gets all the attention and nobody ever died
from a biﬁd uvula or bent ﬁngers. But over time, even a lifetime, the
full phenotypic spectrum of a syndrome is revealed.
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tinct TGFβ3 mutation found in another young girl whose phenotype
only mildly resembles Bea's (Matyas et al., 2014; Rienhoff, 2014). This
year a report was published of 43 patients with TGFβ3 mutations
ascertained on the basis of cardiovascular disease (Bertoli-Avella et al.,
2015). None had variants related to those of Bea's, the loss of a cysteine
amino acid that disrupts a critical structural feature of the TGFβ3 pro-
tein. This keeps open the view that Bea's clinical trajectory is still a mat-
ter of conjecture. One invariant lesson genetics teaches is that different
alleles of a gene can beget different phenotypes, sometimes unpredict-
able, sometimes strikingly different and even paradoxical. So while it
is now clear that mutations in TGFβ3 can cause cardiovascular disease,
the obverse, that all mutations in TGFβ3 cause cardiovascular disease,
formally remains unsubstantiated speculation.
7. Hamartia
No one emerges from a project like this unchanged. Looking inward,
my strengths and weaknesses as a scientist and clinician became more
obvious. The social nature of science, science as a community effort
became very real. I have a greater appreciation for what constitutes a
scientiﬁc fact, the actual burden of scientiﬁc proof. I learned the value
of a coherent narrative not just for enlisting the help of others but to
critically interpret and re-assess the data, ours and others'. I have also
learned that a facile narrative sells well but canmask unexplained com-
plexity. Biology is rarely as simple as it is represented (Lazebnik, 2012).
The goals of the academic community in furthering science are dif-
ferent than those of parents. Parents and patients naturally seek eternal
truths on which to plot certain courses while academics are more skep-
tical of facts, regarding them as ephemeral. There is also the need to “tell
stories” to publish papers and obtain funding. These pressures often
lead the course of investigation away from answering questions parents
have. The academic world is highly competitive requiring greater focus,
speed and ﬁnesse to succeed. My efforts were dismissed by some im-
portant scientists to the point where I stopped introducing myself as a
father but rather as a clinician with an interesting case. Admittedly, I
was unprepared for competition from academics. When ﬁrst reported,
Bea's syndrome was hers alone but it is now subsumed under the
name of another despite a chorus of objections (Pyeritz et al., 2014)
and unmindful of the complexities and practical consequences of noso-
logical designations (von Kodolitsch et al., 2015), those discussions are
among the Professionals, not me. After all, my point in the telling the
world about Bea was to set the world watching for other Beas—these
reports are the ﬁrst echoes of her story. But it reminded me I was still
a pilgrim in a foreign land.
Though I regard the current paradigm of TGFβ pathophysiology as
overly simplistic, I have great faith science will in the long term reﬁne
ideas as well as sift out wrong ones and trend toward a kind of truth. I
am both an optimist and the father of Bea. As the former, I have hope
that the partiality of Providence favors for her an uneventful course
while the latter ensures Bea visits her cardiologist yearly.
8. Desiderata
Bea is a quintessentially normal 11-year-old tomboy—she plays
baseball, enjoys skinning squirrels, keeps a lizard, refuses pink clothing,
loves school. If she were to voice any complaints about her genetics, itmight be that she is a girl. That psychological phenotype is likely to
change.
As to the four questions we ask our doctors, Bea's syndrome has a
name (OMIM 615582), indeed a few! As to what the future holds: we
don't really know. There will be decades of watchful waiting. To the
question, what can we do, the short answer is be vigilant. There are no
obvious or safe medicines that build muscles. As to who can help, we
also answered that for ourselves: there are legions of people willing to
share their knowledge, their knowhow and their creativity.
There are no last steps in a scientiﬁc investigation. The horizon is al-
ways receding as youwalk toward it.We are always left withmysteries.
But none for Beatrice. She has transcended her condition despite the
attention given to it. She has taught me that a few bent ﬁngers, a
weak leg, maybe even the risk of life-threatening vascular disease is
less important than living life fully engaged. She has embraced the
world adapting to its challenges beginning when she was an infant
rolling on the ﬂoor when she could not crawl. She has steadfastly
insisted on engaging rather than withdrawing as a victim of genetics,
self-identifying not by her limitations but by her strengths and interests,
insisting to be in a swim meet knowing she will be last, hiking at half-
pace but seeing the world less blurred. She is so much more than her
DNA. She is remarkable not because she has some rare variant; she is
remarkable because it doesn't matter.
Acknowledgements
I am grateful to Bart Rhoades, Joanne Rienhoff, Nathan Pearson,
Gordon Livingstone, JudyHall and TomDoetschman formaking sugges-
tions to themanuscript. I thank all the authors of the original case report
and their colleagues for their constant application in getting the work
done. The same heartfelt thanks go to the clinicians who have cared
for Beatrice and to the many scientists willing to discuss the science
behind the work. I am especially grateful to my wife Lisa Hane for her
devotion to Bea every step of the way. My ﬁnal thanks go to Beatrice
for her patience and for what she has taught us.
References
Bertoli-Avella, et al., 2015. J. Am. Coll. Cardiol. 65, 1324.
Brunner, et al., 1992. Mol. Endocrinol. 6, 1691.
Daopin, et al., 1992. Science 257, 369.
Derynck, Miyazono, 2008. The TGF-β family. Cold Spring Harbor Press, New York.
Disabella, et al., 2006. Eur. J. Hum. Genet. 14 (1), 34.
Doetschman, 2009. Methods Mol. Biol. 530, 423.
Kaartinen, et al., 1995. Nat. Genet. 11, 415.
Lazebnik, 2012. Cancer Cell 2, 179.
Lee, et al., 2005. Proc. Natl. Acad. Sci. U. S. A. 102, 18117.
Loeys, et al., 2010. J. Med. Genet. 47 (7), 476.
Maher, 2007. Nature 449, 773.
Matyas, et al., 2014. Am. J. Med. Genet. 164A, 2141.
McKusick, 1960. Heritable Disorders of Connective Tissue. C.V. Mosby Company, St. Louis.
McPherron, et al., 1997. Nature 387, 83.
Mittl, et al., 1996. Protein Sci. 5 (7), 1261.
Mizuguchi, et al., 2004. Nat. Genet. 36 (8), 855.
Nawshad, Hay, 2003. J. Cell Biol. 163 (6), 1291.
Proetzel, et al., 1995. Nat. Genet. 11, 409.
Pyeritz, et al., 2014. Genet. Med. 16 (8), 641.
Rienhoff, 2014. Am. J. Med. Genet. A 164A (8), 2144.
Rienhoff, et al., 2013. Am. J. Med. Genet. 161A, 2040.
Schuelke, et al., 2004. N. Engl. J. Med. 350 (26), 2682.
von Kodolitsch, et al., 2015. Appl. Clin. Genet. 16 (8), 137.
